ProMetic Life Sciences Inc is currently preparing a request to the FDA for an idiopathic pulmonary fibrosis Orphan Drug Designation for its new drug candidate PBI-4050.

In a gold standard animal model proven to emulate pulmonary fibrosis in humans, PBI-4050 performed favorably compared to Pirfenidone, the only commercially approved product for such medical use.

PBI-4050 significantly reduced tissue scarring in the lungs otherwise observed in non-treated animals. Moreover, the combination of PBI-4050 and Pirfenidone generated unprecedented reduction of fibrotic markers, indicating the potential for clinically significant improvement and stabilization in lung function.